Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?
This oncology biotech advancing targeted therapies reported a notable insider sale amid ongoing clinical-stage development.
Overview
On June 23, 2026, Stacy Markel, Chief People Officer at Nuvation Bio Inc. (NYSE:NUVB), exercised 125,000 options for Class A Common Stock and sold the resulting shares for a transaction value of approximately $753,000, according to the SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average purchase price ($6.03); post-transaction value based on June 23, 2026 market close (value: $196,849.64).
Details
Nuvation Bio Inc. is a clinical-stage biotechnology company with a diverse pipeline of targeted oncology drug candidates and a focus on novel mechanisms for cancer treatment. The company's strategy centers on advancing differentiated small molecule assets and a proprietary drug-drug conjugate platform to address unmet needs in solid and hematologic cancers. A robust R&D approach and a pipeline spanning multiple modalities position Nuvation Bio to compete in the evolving oncology therapeutics landscape.
Source
Originally published at www.fool.com.